The CCR5δ32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment

Journal of Infectious Diseases

Volumn 182, Issue 2, 2000, Pages 413-419

  Barroga, Charlene F ^a   Raskino, Claire ^c   Fangon, Moena C ^a   Palumbo, Paul E ^d   Baker, Carol J ^e   Englund, Janet A ^f   Spector, Stephen A ^a,b  

^a Institute for Cell Engineering   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5; DIDANOSINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR; PLACEBO;

ALLELE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; ETHNIC GROUP; GENE DELETION; GENE FREQUENCY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; PRESCHOOL CHILD; RACE; CHILD; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GENOTYPE; INFANT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION;

ALLELES; ANTI-HIV AGENTS; CHILD, PRESCHOOL; CLINICAL TRIALS; CONTINENTAL POPULATION GROUPS; DIDANOSINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ETHNIC GROUPS; GENE FREQUENCY; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; SEQUENCE DELETION; ZIDOVUDINE;

EID: 0033623685     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315704     Document Type: Article

References (38)

1. + cells is mediated by the chemokine receptor CC-CKR-5
2. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
3. Identification of a major co-receptor for primary isolates of HIV-1
4. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
5. Homozygous defect in HIV-1 co-receptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
6. Resistance to HIV- 1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene
7. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
8. The role of mutant CCR5 allele in HIV-1 transmission and disease progression
9. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
10. CCR5 promoter polymorphism and HIV-1 disease progression: Multicenter AIDS Cohort Study (MACS)
11. Genetic acceleration of AIDS progression by a promoter variant of CCR5
12. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants
13. Clinical significance of human immunodefiency virus type 1 phenotypes in infected children
14. CCR5del32 in perinatal HIV-1 infection
15. Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/delta32ccr5 heterozygotes
16. Distribution of CCR5Δ32 allele in Argentinian children at risk of HIV-1 infections: Its role in vertical transmission
17. Role of CCR5 chemokine receptor gene in vertical human immunodeficiency virus type 1 transmission and disease progression
18. CCR5 genotype and HIV-1 infection in perinatally-exposed infants
19. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children: French Pediatric HIV Infection Study Group
20. Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasmia virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age
21. Distribution of CCR5delta32 in human immunodeficiency virus-infected children and its relationship to disease course
22. Clinical and laboratory characteristics of a large cohort of symptomatic, human immunodeficiency virus-infected infants and children
23. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-1 infected children
24. Chemokine receptors and neurocognitive disorders
25. + lymphocyte count in HIV-infected infants and children
26. Neurological, neurocognitive and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens: Pediatric AIDS Clinical Trials Group 152 Study Team
27. Neurologic manifestations of human immunodeficiency virus infection in children
28. Neurological and developmental problems in pediatric HIV infection
29. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age
30. Localization of HIV-1 co-receptors CCR5 and CXCR4 in the brain of children with AIDS
31. HIV-1 infection of the developing nervous system: Central role of astrocytes in pathogenesis
32. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia
33. Chemokine receptors in the human brain and their relationship to HIV infection
34. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression: Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study
35. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation
36. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant: ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)